RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Tweet Send to a Friend
RBC Capital analyst Lisa Walter reiterated an Outperform rating and $40.00 price target on 4D Molecular Therapeutics (NASDAQ: FDMT).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


